Pearl Steinzor

A prospective registry study suggests cardiac MRI scar burden and biomarkers may refine prognostic assessment beyond current sudden cardiac death models.

New scientific statement argues that heart failure with mildly reduced ejection fraction should no longer be treated as a “gray zone.”

A growing body of heart failure evidence highlights the role of metabolic therapies, precision phenotyping, and next-generation mineralocorticoid receptor antagonists.

Three hospital systems claim CVS Health secretly pocketed 340B savings meant for indigent care.

A turbulent regulatory environment is forcing covered entities to rethink how they manage 340B compliance.

Two posters presented at the EASL Congress 2026 highlight promising clinical and preclinical findings for AHB-137.

The approval is based on results from MannKind's phase 3 INHALE-1 clinical trial.

Heiner Wedemeyer, MD, offered an unflinching assessment of viral hepatitis medicine, celebrating landmark breakthroughs while issuing a clear warning that the field is failing the populations it set out to protect.

Two posters presented at EASL 2026 clarify where peginterferon alfa-2b fits in therapy for patients with chronic hepatitis B.

New data showed durable hepatitis D virus RNA suppression through 96 weeks with tobevibart plus elebsiran, while higher BMI appeared to affect ALT normalization.